Skip to Main Content

Author Details

Bishoy M Faltas
Sandra and Edward Meyer Cancer Center
2007
65
20
PMIDPaper TitleJournal TitlePublished Year
37802683Novel Use of Circulating Tumor DNA to Identify Muscle-invasive and Non-organ-confined Upper Tract Urothelial Carcinoma.Eur Urol2024
36480186The Cytidine Deaminase APOBEC3G Contributes to Cancer Mutagenesis and Clonal Evolution in Bladder Cancer.Cancer Res2023
37561425Immunotherapy in the Treatment of Localized Genitourinary Cancers.JAMA Oncol2023
37832869Elucidating the Role of PIK3CA in Early-Stage Bladder Tumorigenesis: New Insights from a Novel Transgenic Mouse Model.Am J Pathol2023
37609344Combinatorial genetic strategy accelerates the discovery of cancer genotype-phenotype associations.bioRxiv2023
37353441A Pilot Study on Hyperthermic Intraperitoneal Chemotherapy after Radical or Partial Cystectomy with Pelvic Lymph Node Dissection for High-risk Muscle-invasive Bladder Cancer.Eur Urol2023
37217696Author Correction: Circulating and urinary tumour DNA in urothelial carcinoma - upper tract, lower tract and metastatic disease.Nat Rev Urol2023
37043205Immune Checkpoint Inhibitors and Long-term Survival of Patients With Metastatic Urothelial Cancer.JAMA Netw Open2023
36977797Circulating and urinary tumour DNA in urothelial carcinoma - upper tract, lower tract and metastatic disease.Nat Rev Urol2023
35046520Serial ctDNA analysis predicts clinical progression in patients with advanced urothelial carcinoma.Br J Cancer2022
35710704Recurrent exon-deleting activating mutations in AHR act as drivers of urinary tract cancer.Sci Rep2022
35693069Loss of function mutations in <i>CDKN1A</i> are permissive for APOBEC3-induced mutagenesis in urothelial carcinoma.Am J Cancer Res2022
35483877Tumor-immune microenvironment revealed by Imaging Mass Cytometry in a metastatic sarcomatoid urothelial carcinoma with a prolonged response to pembrolizumab.Cold Spring Harb Mol Case Stud2022
36129800Tumor-Infiltrating Myeloid Cells Confer De Novo Resistance to PD-L1 Blockade through EMT-Stromal and Tgfβ-Dependent Mechanisms.Mol Cancer Ther2022
33190043Integration of whole-exome and anchored PCR-based next generation sequencing significantly increases detection of actionable alterations in precision oncology.Transl Oncol2021
33826550Impact of Use of Antibiotics on Response to Immune Checkpoint Inhibitors and Tumor Microenvironment.Am J Clin Oncol2021
34385467Functional comparison of exome capture-based methods for transcriptomic profiling of formalin-fixed paraffin-embedded tumors.NPJ Genom Med2021
34286887Validation of a Circulating Tumor DNA-Based Next-Generation Sequencing Assay in a Cohort of Patients with Solid tumors: A Proposed Solution for Decentralized Plasma Testing.Oncologist2021
31412004Circulating Tumor DNA Alterations in Advanced Urothelial Carcinoma and Association with Clinical Outcomes: A Pilot Study.Eur Urol Oncol2020
31982787The emerging landscape of germline variants in urothelial carcinoma: Implications for genetic testing.Cancer Treat Res Commun2020
33273457Common germline-somatic variant interactions in advanced urothelial cancer.Nat Commun2020
32571725Molecular Characterization of Upper Tract Urothelial Carcinoma in the Era of Next-generation Sequencing: A Systematic Review of the Current Literature.Eur Urol2020
32439865Epithelial plasticity can generate multi-lineage phenotypes in human and murine bladder cancers.Nat Commun2020
32235944Genomic heterogeneity in bladder cancer: challenges and possible solutions to improve outcomes.Nat Rev Urol2020
30558440Rationale for co-targeting CDK4/6 and FGFR pathways in urothelial carcinoma.Expert Opin Ther Targets2019
30171455The molecular limitations of biomarker research in bladder cancer.World J Urol2019
31387980Proteomic and genomic signatures of repeat instability in cancer and adjacent normal tissues.Proc Natl Acad Sci U S A2019
31525487Clinical features of neuroendocrine prostate cancer.Eur J Cancer2019
31278255Upper tract urothelial carcinoma has a luminal-papillary T-cell depleted contexture and activated FGFR3 signaling.Nat Commun2019
31592503Integrative Molecular Analysis of Patients With Advanced and Metastatic Cancer.JCO Precis Oncol2019
30865916Oncogenic Addiction to ERBB2 Signaling Predicts Response to Trastuzumab in Urothelial Cancer.J Natl Compr Canc Netw2019
28988653Metastasectomy in older adults with urothelial carcinoma: Population-based analysis of use and outcomes.Urol Oncol2018
29720713Treatment resistance in urothelial carcinoma: an evolutionary perspective.Nat Rev Clin Oncol2018
29517810Characterization of metastatic urothelial carcinoma via comprehensive genomic profiling of circulating tumor DNA.Cancer2018
27939401Immune-checkpoint blockade in cisplatin-ineligible patients with urothelial cancer.Lancet2017
28331002Personalized In Vitro and In Vivo Cancer Models to Guide Precision Medicine.Cancer Discov2017
29333526Next-Generation Rapid Autopsies Enable Tumor Evolution Tracking and Generation of Preclinical Models.JCO Precis Oncol2017
26923782Blocking immune checkpoints in prostate, kidney, and urothelial cancer: An overview.Urol Oncol2016
26541586Sacituzumab Govitecan, a Novel Antibody--Drug Conjugate, in Patients With Metastatic Platinum-Resistant Urothelial Carcinoma.Clin Genitourin Cancer2016
27749842Clonal evolution of chemotherapy-resistant urothelial carcinoma.Nat Genet2016
27427223Effect of tumor location on survival in urinary bladder adenocarcinoma: A population-based analysis.Urol Oncol2016
26916979Application of next-generation sequencing in gastrointestinal and liver tumors.Cancer Lett2016
25709026Recurrence patterns after open and robot-assisted radical cystectomy for bladder cancer.Eur Urol2015
26181256Whole-Exome Sequencing of Metastatic Cancer and Biomarkers of Treatment Response.JAMA Oncol2015
26142590Radical Cystectomy for Bladder Cancer in Patients With and Without a History of Pelvic Irradiation: Survival Outcomes and Diversion-related Complications.Urology2015
25633079Novel molecular targets for urothelial carcinoma.Expert Opin Ther Targets2015
24596445Immunologics and chemotherapeutics for renal cell carcinoma.Semin Intervent Radiol2014
23098263Sustained remission in a patient with myelodysplastic syndrome and a complex karyotype after erythropoiesis-stimulating therapy followed by colonic T-cell lymphoblastic lymphoma.Leuk Lymphoma2013
24094045Myelodysplastic syndromes: toward a risk-adapted treatment approach.Expert Rev Hematol2013
23666619Myelodysplastic syndromes: what do hospitalists need to know?J Hosp Med2013
  • 1 - 50 of 65

Recommended Authors

Felipe Batalini
Mayo Clinic Arizona
Career Start Year 2015
Number of shared co-authors 0
Stephanie A Wankowicz
University of California San Francisco
Career Start Year 2014
Number of shared co-authors 11
Eliezer M Van Allen
Dana-Farber Cancer Institute
Career Start Year 2009
Number of shared co-authors 25
Ashiq Masood
Indiana University Melvin and Bren Simon Comprehensive Cancer Center
Career Start Year 2008
Number of shared co-authors 0
Linghua Wang
The University of Texas M. D. Anderson
Career Start Year 2006
Number of shared co-authors 0
Alan H Bryce
Mayo Clinic
Career Start Year 2006
Number of shared co-authors 3
Jonathan Chou
University of California san francisco
Career Start Year 2005
Number of shared co-authors 5
Albrecht Stenzinger
Institute of Pathology, University Hospital Heidelberg
Career Start Year 2005
Number of shared co-authors 1
Jochen K Lennerz
Massachusetts General Hospital/Harvard Medical School
Career Start Year 2004
Number of shared co-authors 2
Pavlos Msaouel
The University of Texas MD Anderson Cancer Center
Career Start Year 2004
Number of shared co-authors 3
Philippe L Bedard
Princess Margaret Cancer Centre, University Health Network
Career Start Year 2002
Number of shared co-authors 0
Michiel S van der Heijden
the Netherlands Cancer Institute-Antoni van Leeuwenhoek Hospital
Career Start Year 2002
Number of shared co-authors 10
Jes??s Garc??a-Donas
HM Hospitales-Centro Integral Oncologico Clara Campal
Career Start Year 2001
Number of shared co-authors 2
Syed A Hussain
University of Sheffield and Sheffield Teaching Hospitals
Career Start Year 2001
Number of shared co-authors 5
Brian A Costello
The Mayo Clinic
Career Start Year 2001
Number of shared co-authors 1
David T Miyamoto
Massachusetts General Hospital
Career Start Year 2000
Number of shared co-authors 1
Pingfu Fu
Case Western Reserve University
Career Start Year 2000
Number of shared co-authors 2
Martijn P Lolkema
Erasmus MC Cancer Institute
Career Start Year 1999
Number of shared co-authors 2
Thomas J George
UF Health Cancer Center
Career Start Year 1998
Number of shared co-authors 9
Anthony J Iafrate
Massachusetts General Hospital
Career Start Year 1997
Number of shared co-authors 3
Charles Swanton
Francis Crick Institute
Career Start Year 1997
Number of shared co-authors 8
Nam Bui
Stanford University
Career Start Year 1996
Number of shared co-authors 0
Jorge Nieva
Norris Comprehensive Cancer Center, University of Southern California
Career Start Year 1995
Number of shared co-authors 0
Stefan Sleijfer
Erasmus MC Cancer Institute, University Medical Center Rotterdam
Career Start Year 1994
Number of shared co-authors 1
David I Quinn
USC Norris Comprehensive Cancer Center
Career Start Year 1993
Number of shared co-authors 5
Craig Gedye
Hunter Medical Research Institute, University of Newcastle
Career Start Year 1993
Number of shared co-authors 2
Paul T Fanta
University of California San Diego Moores Cancer Center
Career Start Year 1992
Number of shared co-authors 1
Mark Lawler
Queens University Belfast Belfast
Career Start Year 1988
Number of shared co-authors 1
Jose A Lopez-Martin
Hospital Universitario 12 de Octubre
Career Start Year 1988
Number of shared co-authors 0
David M Berman
Queen's University
Career Start Year 1982
Number of shared co-authors 3

Collaborators

Olivier Elemento
Meyer Cancer Center
Co-authored papers 17
Scott T Tagawa
Meyer Cancer Center, Weill Cornell Medicine-NewYork Presbyterian Hospital
Co-authored papers 15
Juan Miguel Mosquera
Caryl and Israel Englander Institute for Precision Medicine
Co-authored papers 14
David M Nanus
Sandra and Edward Meyer Cancer Center
Co-authored papers 12
Andrea Sboner
Institute for Computational Biomedicine
Co-authored papers 12
Himisha Beltran
Dana-Farber Cancer Institute
Co-authored papers 10
Ana M Molina
Englander Institute for Precision Medicine
Co-authored papers 10
Rohan Bareja
Case Western Reserve University
Co-authored papers 9
Brian D Robinson
Sandra and Edward Meyer Cancer Center
Co-authored papers 9
Kenneth Eng
Caryl and Israel Englander Institute for Precision Medicine
Co-authored papers 8
Mark A Rubin
University of Bern
Co-authored papers 8
David Wilkes
Caryl and Israel Englander Institute for Precision Medicine.
Co-authored papers 6
Francesca Demichelis
University of Trento
Co-authored papers 6
Cora N Sternberg
Meyer Cancer Center, Englander Institute for Precision Medicine
Co-authored papers 6
Douglas S Scherr
New York-Presbyterian Hospital
Co-authored papers 6
Michael Sigouros
Caryl and Israel Englander Institute for Precision Medicine
Co-authored papers 5
Davide Prandi
University of Trento
Co-authored papers 5
Noah Greco
Caryl and Israel Englander Institute for Precision Medicine
Co-authored papers 4
Chantal Pauli
University Hospital Zurich
Co-authored papers 4
Jenny Xiang
Caryl and Israel Englander Institute for Precision Medicine.
Co-authored papers 4
David J Pisapia
NewYork-Presbyterian Hospital - Weill Cornell Medicine
Co-authored papers 4
Kentaro Ohara
Caryl and Israel Englander Institute for Precision Medicine.
Co-authored papers 4
Bhavneet Bhinder
Memorial Sloan Kettering Cancer Center, USA Memorial Sloan Kettering Cancer Center
Co-authored papers 4
Philippe E Spiess
H. Lee Moffitt Cancer Center and Research Institute
Co-authored papers 4
Aram Vosoughi
H. Lee Moffitt Cancer Center and Research Institute
Co-authored papers 4
Rema Rao
Montefiore Medical Center/Albert Einstein College of Medicine
Co-authored papers 4
Robert Kim
University of California
Co-authored papers 3
Shaham Beg
New York-Presbyterian Hospital-Weill Cornell Medical College
Co-authored papers 3
Joanna Cyrta
Paris Sciences Lettres University PSL, Institut CURIE
Co-authored papers 3
Rebecca Nagy
Guardant Health Inc.
Co-authored papers 3
Release 1.2